North Eastern German Society of Gynaecological Oncology
26
3
8
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.5%
3 terminated/withdrawn out of 26 trials
83.3%
-3.2% vs industry average
31%
8 trials in Phase 3/4
27%
4 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (26)
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Role: collaborator
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer
Role: lead
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Role: collaborator
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Role: collaborator
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
Role: collaborator
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Role: lead
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Role: collaborator
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Role: collaborator
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Role: lead
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
Role: lead
AXillary Surgery After NeoAdjuvant Treatment
Role: collaborator
Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)
Role: collaborator
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Role: lead
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Role: lead
Pazopanib Vs. Pazopanib Plus Gemcitabine
Role: lead
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Role: lead
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Role: collaborator
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Role: collaborator
Rucaparib Maintenance Therapy in Advanced Cervical Cancer
Role: collaborator
Taxol Carboplatin and Erythropoetin
Role: lead